Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q3FY25 results Total Income at Rs 10,250 million, decline of 6.1% YoY, decline of 2.1% QoQ. Adjusted EBITDA of Rs 1,359 million, up 12.1% YoY, up 0.9% QoQ. Adj EBITDA Margin at 13.3%, Adj PAT Margin at 6.5%. Adjusted PAT of Rs 663 million, up 15.2% YoY, decline of 0.5% QoQ. Sanjeev Jain, Managing Director, said: “Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a EUR 200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.” Sandeep Jain, Managing Director, said: “We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.” Result PDF
Pharmaceuticals company Akums Drugs & Pharmaceuticals announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Adjusted PAT of Rs 667 million,up 16.2% QoQ, up by 8.9% YOY. Adj EBITDA Margin at 12.9%; Adj PAT Margin at 6.4%. Total Income at Rs 10,466 million,Growth of 2.0% QoQ, down of 11.9% YoY. Adjusted EBITDA of Rs 1,347 million,up 3.0% QoQ, down 28.0% YoY H1FY25 Financial Highlights: Adjusted PAT of Rs 1,240 million, up by 25.4%. Adj EBITDA Margin at 12.8%; Adj PAT Margin at 6.0%. Total Income at Rs 20,722 million, down of 4.3% YoY. Adjusted EBITDA of Rs 2,654 million, down 10.1% YoY. Cash surplus at Rs 3,406 million. Sanjeev Jain, Managing Director, said: “Short term volatility apart, we continue to see strong secular demand for outsourced drug development and manufacturing. We will continue to invest in building world-class capabilities to help our clients launch new formulations and therapies, and drive their growth. The company is taking long term measures to further strengthen its leadership position in the CDMO space.” “Our focus continues to be on the development of innovative products and platforms, exploring more markets towards our larger objective of driving profitable growth. Q2 business performance reflects the muted volume demand and low API prices. We remain committed to our long term vision of being a global CDMO player”. Result PDF